Breakthrough Therapy Designation granted to zoldonrasib for previously treated KRAS G12D-mutated locally advanced or metastatic NSCLC January 11, 2026
AbbVie secured global rights outside China to ZG006 (alveltamig) developed by Suzhou Zelgen Biopharmaceuticals January 4, 2026
Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) + Pembrolizumab for 1L PD-L1-Positive NSCLC January 4, 2026
Jacobio Pharma Enters Global Exclusive License Agreement with AstraZeneca for Pan-KRAS Inhibitor JAB-23E73 December 30, 2025
Faron announces strategic collaboration with The Institute for Cancer Research to launch BLAZE trial of bexmarilimab + zimberelimab December 30, 2025
First Patient Dosed in Ph 3 ALPACCA Trial of Firmonertinib in 1L EGFR PACC Mutant NSCLC December 30, 2025
FAILED TRIAL: LATIFY Ph 3 trial of ceralasertib + Imfinzi did not meet the OS primary endpoint vs SOC docetaxel in NSCLC patients December 30, 2025
Trethera Receives $2.7M NIH Grant for TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer December 22, 2025
US FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and LAZCLUZE® (lazertinib) combo for 1L EGFRm NSCLC December 22, 2025
BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline Including OMNI-EGFR Inhibitor for NSCLC December 15, 2025
Immutep and Dr. Reddy’s enter Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 15, 2025
New Analyses of DUBLIN-3 Ph 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for NonSq EGFR WT NSCLC and a Reduction in Brain Mets Compared to Docetaxel Announced December 15, 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant OS improvement for Asian patients with EGFR-mutated NSCLC in the Ph 3 MARIPOSA study December 9, 2025
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of Eftilagimod Alfa December 9, 2025
Takeda Announces Closing of Strategic Partnership with Innovent Biologics for Next-Gen Investigational Oncology Medicines December 9, 2025
Additional Positive LP-184 Ph 1a Results Reported Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients December 9, 2025
First-in-Human Data from Ph 1 Trial of GTA182 in MTAP-Deleted Advanced NSCLC presented December 9, 2025
Clinically Meaningful OS Benefit for Gotistobart in Patients with Previously Treated Squamous NSCLC Announced December 9, 2025
